Four-year survival after trans-jugular intrahepatic porto-systemic shunt for veno-occlusive disease following autologous bone marrow transplantation.
Severe hepatic veno-occlusive disease is still a potentially lethal complication after bone marrow transplantation. We here report the case of a patient who developed liver veno-occlusive disease with severe hemodynamic dysfunction and was successfully treated by means of a trans-jugular intrahepatic portosystemic shunt. After three years, he is still disease-free with a functioning shunt and a normal laboratory liver profile. A trans-jugular intrahepatic portosystemic shunt is a treatment option that has been used in very few patients affected by hepatic veno-occlusive disease; its indications and timing remain to be established.
Annaloro
Claudio
C
Department of Hematology, Ospedale Maggiore di Milano, IRCCS, Via F Sforza, 35 - 20122 Milano, Italy.
Robbiolo
Livia
L
Pozzoli
Ermanno
E
Ibatici
Adalberto
A
Nicolini
Antonio
A
Salerno
Francesco
F
Deliliers
Giorgio Lambertenghi
GL
D000328:Adult; D002330:Carmustine / Q000009:adverse effects; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000009:adverse effects; D005047:Etoposide / Q000009:adverse effects; D006439:Hemodynamics; D006504:Hepatic Veno-Occlusive Disease / Q000139:chemically induced / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007601:Jugular Veins; D017728:Lymphoma, Large-Cell, Anaplastic / Q000628:therapy; D008297:Male; D036102:Peripheral Blood Stem Cell Transplantation; D011170:Portasystemic Shunt, Surgical; D012074:Remission Induction; D019851:Thrombophilia / Q000209:etiology; D019172:Transplantation Conditioning / Q000009:adverse effects; D014182:Transplantation, Autologous
D005047:Etoposide; D003520:Cyclophosphamide; D002330:Carmustine